Galectin-3 for risk stratification in acute coronary syndrome

Kaynakça (10)

1. Salvagno GL, Pavan C. Prognostic biomarkers in acute coronary syndrome. Ann Transl Med 2016;4:258
2. Quisi A, Alıcı G, Genç Ö, Harbalıoğlu H, Kurt İH. The relationship between galectin-3 and SYNTAX score I in patients with non-ST-segment elevation myocardial infarction. Turk Kardiyol Dern Ars 2020;48:723-30
3. Yadav M, Palmerini T, Caixeta A, Madhavan MV, Sanidas E, Kirtane AJ, et al. Prediction of coronary risk by SYNTAX and derived scores: synergy between percutaneous coronary intervention with taxus and cardiac surgery. J Am Coll Cardiol 2013;62:1219−30
4. Elola MT, Wolfenstein-Todel C, Troncoso MF, Vasta GR, Rabinovich GA. Galectins: matricellular glycan-binding proteins linking cell adhesion, migration, and survival. Cell Mol Life Sci 2007;64:1679−700
5. Suarez G, Meyerrose G. Heart failure and galectin 3. Ann Transl Med 2014;2:86
6. Winter MP, Wiesbauer F, Alimohammadi A, Blessberger H, Pavo N, Schillinger M, et al. Soluble galectin-3 is associated with premature myocardial infarction. Eur J Clin Invest 2016;46:386−91
7. Falcone C, Lucibello S, Mazzucchelli I, Bozzini S, D’Angelo A, Schirinzi S, et al. Galectin-3 plasma levels and coronary artery disease: a new possible biomarker of acute coronary syndrome. Int J Immunopathol Pharmacol 2011;24:905−13
8. Gucuk Ipek E, Akin Suljevic S, Kafes H, Basyigit F, Karalok N, Guray Y, et al. Evaluation of galectin-3 levels in acute coronary syndrome. Ann Cardiol Angeiol (Paris) 2016;65:26−30
9. Singsaas EG, Manhenke CA, Dickstein K, Orn S. Circulating Galectin-3 Levels Are Increased in Patients with Ischemic Heart Disease, but Are Not Influenced by Acute Myocardial Infarction. Cardiology 2016;134:398−405
10. Hackler E 3rd, Lew J, Gore MO, Ayers CR, Atzler D, Khera A, et al. Racial Differences in Cardiovascular Biomarkers in the General Population. J Am Heart Assoc 2019;8:e012729.